News for Harmony Biosciences Holdings, Inc. (HRMY)

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2024 financial results on Tuesday, February

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Harmony Biosciences Holdings, Inc (NASDAQ:HRMY) stands against the other...

Biotechnology stocks are among the most volatile in the market due to their high risk.

Harmony Biosciences Holdings, Inc.'s strong revenue growth, diverse pipeline, and undervalued stock make it a compelling buy. Click for my HRMY stock update.

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Harmony Biosciences Holdings, Inc.

PR NewswirePLYMOUTH MEETING, Pa., Dec. 3, 2024 PLYMOUTH MEETING, Pa., Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today

PR NewswirePLYMOUTH MEETING, Pa., Nov. 21, 2024 PLYMOUTH MEETING, Pa., Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), tod

Learn about the potential expansion of Harmony Biosciences Holdings, Inc.'s WAKIX for idiopathic hypersomnia patients. Click for more on HRMY stock prospects.

Tuesday's Insider Trades: Major Buys and Sells in US Stocks Revealed

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

Net Revenue: $186 million for Q3 2024.Cumulative Net Revenue for WAKIX: Surpassed $2 billion since launch.2024 Net Revenue Guidance: $700 million to $720 milli

Read the latest healthcare industry dashboard see which 10 healthcare stocks are cheaper than their peers in August.

Harmony's Q3 2023 earnings saw Wakix revenues up 37% YoY and net income of $38.5 million. Read the reasons I upgrade HRMY stock's rating to a buy.

Raymond James lifts Harmony Biosciences target on steady net patient adds

CURE - why most investors should stay away from this healthcare ETF. Click here to know more.

Continued Strong Growth with WAKIX® Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,800...

Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc.

Item 2.01. Completion of Acquisition or Disposition of Assets. On October 10, 2023, Harmony Biosciences...